Ziping Wang

Peking University - Department of Thoracic Medical Oncology

Beijing

China

SCHOLARLY PAPERS

3

DOWNLOADS

165

TOTAL CITATIONS

0

Scholarly Papers (3)

1.

Sintilimab Plus Bevacizumab Biosimilar IBI305, and Chemotherapy for Patients with EGFR-Mutant Nonsquamous NSCLC Who Progressed on EGFR-TKI Therapy (ORIENT-31): Interim Results from a Randomized, Double-Blind, Phase 3 Study

Number of pages: 38 Posted: 18 Mar 2022
Shanghai Jiao Tong University (SJTU) - Shanghai Lung Cancer Center, Central South University - Thoracic Medicine Department II, Shanghai Jiao Tong University (SJTU) - Department of Medical Oncology, Jilin Cancer Hospital - Department of Oncology, Zhengzhou University - Henan Cancer Hospital, Peking University - Department of Thoracic Medical Oncology, Peking University - Department of Thoracic Medical Oncology, Huazhong University of Science and Technology - Hubei Cancer Hospital, Shandong First Medical University - Department of Oncology, Xuzhou Central Hospital, Nanjing University - Department of Respiratory Medicine, Hebei Medical University, Jilin University (JLU) - Cancer Center, Capital Medical University - Beijing Tuberculosis and Thoracic Tumor Research Institute, University of Science and Technology of China (USTC) - Department of Thoracic Cancer Chemotherapy, Zhengzhou University - Department of Oncology, Xiamen University, Nanjing University, Sichuan University - Department of Respiratory and Critical Care Medicine, Zhengzhou University - Henan Provincial People's Hospital, Innovent Biologics, Inc. - Department of Medical Science and Strategy Oncology, Innovent Biologics, Inc. - Department of Biostatistics and Information, Eli Lilly and Company, Ltd - Department of Oncology Medical Strategy, Eli Lilly and Company, Ltd - Clinical Design, Delivery & Analytics, Innovent Biologics, Inc. - Department of Medical Science and Strategy Oncology, Innovent Biologics, Inc. - Department of Biostatistics and Information and Innovent Biologics, Inc. - Department of Medical Science and Strategy Oncology
Downloads 95 (565,488)

Abstract:

Loading...

sintilimab, IBI305, NSCLC, EGFR

2.

Toripalimab Plus Chemotherapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (Choice-01): Final Os and Biomarker Exploration of a Randomized, Double-Blind, Phase 3 Trial

Number of pages: 37 Posted: 02 Aug 2024
Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology, Central South University - Thoracic Medicine Department II, Capital Medical University - Beijing Tuberculosis and Thoracic Tumor Research Institute, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology, Jilin Cancer Hospital, China Medical University - Medical Oncology Department of Thoracic Cancer, Guangdong Pharmaceutical University - Department of Medical Oncology, Xuzhou Central Hospital, Jiangnan University - Affiliated Hospital, Chinese Academy of Sciences (CAS) - Key Laboratory on Diagnosis and Treatment Technology on Thoracic Cancer, Harbin Medical University, Wenzhou Medical University - Taizhou Hospital of Zhejiang Province, Linyi Cancer Hospital - Department of Medical Oncology, Zhejiang University - Second Affiliated Hospital, The First Affiliated Hospital of Guangxi Medical University, Shanghai Jiao Tong University (SJTU) - Department of Respiratory and Critical Care Medicine, Tangshan People’s Hospital, Shandong University - Shandong Cancer Hospital, Qingdao Central Hospital, ZhongDa Hospital of Southeast University, Huazhong University of Science and Technology - Department of Medical Oncology, Nanchang University - First Affiliated Hospital, Zhengzhou University - Henan Cancer Hospital, Government of the People's Republic of China - Second People's Hospital of Yibin, Peking University - Department of Thoracic Medical Oncology, Medical School of Nanjing University, Xiamen University - First Affiliated Hospital, Nanjing Medical University - Jiangsu Cancer Hospital, Zhengzhou University - Department of Oncology, Xinjiang Medical University - Affiliated Tumor Hospital, China Medical University - Department of Medical Oncology, Qingdao University - Affiliated Hospital, Nanchang University - Department of Medical Oncology, Shandong University - Qilu Hospital, Shanghai Pulmonary Hospital, Tianjin Medical University - Department of Medical Oncology, Nanjing University - Department of Respiratory Medicine, Anhui Provincial Cancer Hospital, Anhui Medical University - Department of Respiratory and Critical Care Medicine, Guangzhou Medical University - Second Affiliated Hospital, Army Medical University, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Peking Union Medical College Hospital, Tongji University - Department of Respiratory and Critical Care Medicine, Nantong Tumor Hospital - Department of Medical Oncology, First People's Hospital of Changzhou, Chongqing Medical University - Second Affiliated Hospital, Jilin University (JLU) - Cancer Center, Shanghai Jiao Tong University (SJTU) - Ruijin Hospital of Shanghai, Yangzhou University - Subei People's Hospital of Jiangsu Province, Anhui Provincial Cancer Hospital, Shanxi Provincial People's Hospital, Shanxi Provincial People's Hospital, Chinese Academy of Medical Sciences - Cancer Hospital, Nanjing Medical University - Nanjing First Hospital, Nanjing Medical University - Department of Oncology, ChangZhou Cancer Hospital, Nantong University - Department of Respiratory Medicine, First Hospital of Jiaxing, Fujian Provincial Cancer Hospital, Ground Force Medical University - Xinqiao Hospital, Xi’an Jiaotong University, Health Science Center, First Affiliated Hospital, TopAlliance Biosciences, TopAlliance Biosciences, Burning Rock Biotech - Department of Medicine, Burning Rock Biotech, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC), Shanghai Junshi Biosciences Co., LTD, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - State Key Laboratory of Molecular Oncology and Chinese Academy of Medical Sciences & Peking Union Medical College - State Key Laboratory of Molecular Oncology
Downloads 45 (826,310)

Abstract:

Loading...

Non-small cell lung cancer, overall survival, immunotherapy, biomarker

3.

Prognostic Significance and Adjuvant Therapy Benefits in Patients with Resected Stage I Lung Adenocarcinoma with Micropapillary Pattern

Number of pages: 29 Posted: 29 Dec 2023
Beijing Cancer Hospital, Beijing Cancer Hospital, Beijing Cancer Hospital, Chinese Academy of Sciences (CAS), University of Texas at Houston - Department of Thoracic/Head and Neck Medical Oncology, Peking University, Beijing Cancer Hospital, Beijing Cancer Hospital, Beijing Cancer Hospital, Beijing Cancer Hospital, Beijing Cancer Hospital, Beijing Cancer Hospital, Beijing Cancer Hospital, Beijing Cancer Hospital, Peking University - Peking University Cancer Hospital & Institute, Beijing Cancer Hospital, Beijing Cancer Hospital, Beijing Cancer Hospital, Beijing Cancer Hospital, Beijing Cancer Hospital, Beijing Cancer Hospital, Beijing Cancer Hospital, Beijing Cancer Hospital, Beijing Cancer Hospital, Beijing Cancer Hospital, Beijing Cancer Hospital, Beijing Cancer Hospital, Peking University - Key Laboratory of Carcinogenesis and Translational Research, Mayo Clinic, Peking University - Thoracic Oncology Institute and Peking University - Department of Thoracic Medical Oncology
Downloads 25 (1,031,689)

Abstract:

Loading...

lung adenocarcinoma, micropapillary, stage I, recurrence-free survival, adjuvant chemotherapy